Save
Email
Print
ShareFeb. 13, 2008 — The prototypical member of the VEGF family of proteins, VEGF, has recently been shown to protect cells in the nervous system from death and degeneration. However, its clinical utility in this regard is limited, because it also induces blood vessel growth, a process known as angiogenesis.
In a new study, Xuri Li and colleagues at the National Institutes of Health, Bethesda, have revealed that the VEGF family member VEGF-B acts as a potent inhibitor of murine retinal cell death while exerting minimal angiogenic effects.
In addition to inhibiting expression of cell-death--related genes, VEGF-B was shown to reduce the death of murine retinal cells in culture models of cellular injury and in mouse models of ocular neurodegenerative disorders.
Furthermore, VEGF-B treatment inhibited brain cell death in a mouse model of stroke.
As the concentration of VEGF-B required for retinal protection did not lead to angiogenesis in the mouse retina, the authors concluded that VEGF-B might provide a new therapeutic option for the treatment of neurodegenerative disease.
Journal reference: VEGF-B inhibits apoptosis via VEGFR-1--mediated suppression of the expression of BH3-only protein genes in mice and rats. Journal of Clinical Investigation. February 8, 2008.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
more 
